Recombinant Human CCL17 protein

CCL17 (C-C motif chemokine ligand 17), also known as thymus and activation-regulated chemokine (TARC), is a small secreted protein belonging to the CC chemokine family. It is primarily produced by dendritic cells, macrophages, and endothelial cells, playing a pivotal role in immune regulation by recruiting T helper 2 (Th2) cells, regulatory T cells (Tregs), and other CCR4-expressing leukocytes to inflammatory sites. CCL17 binds specifically to the CCR4 receptor, initiating signaling cascades that mediate chemotaxis and modulate immune responses in conditions such as allergic inflammation, autoimmune diseases, and cancer.

Recombinant CCL17 proteins are engineered using genetic recombination techniques to produce highly purified, biologically active forms of the chemokine. These proteins are typically expressed in mammalian cell systems (e.g., HEK293 or CHO cells) or prokaryotic systems (e.g., E. coli), with mammalian-derived versions often retaining post-translational modifications critical for receptor interaction. The recombinant form enables precise study of CCL17's functions in vitro and in vivo, including its role in Th2-polarized immune responses, tumor microenvironment modulation, and vascular inflammation. Researchers utilize it to investigate therapeutic targets for diseases like atopic dermatitis, asthma, and certain malignancies where CCL17/CCR4 signaling is dysregulated. Quality-controlled batches ensure consistency in experimental and preclinical studies, supporting drug discovery and mechanistic research.